<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00945958</url>
  </required_header>
  <id_info>
    <org_study_id>CLR_09_13</org_study_id>
    <nct_id>NCT00945958</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharma Advanced Research Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Pharma Advanced Research Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the long-term safety of SPARC0913. A multicenter,
      open label, non-randomized, uncontrolled, single group assignment, safety study of subjects
      with primary open angle glaucoma or ocular hypertension is planned. Subjects will receive
      study medication for a period of 24-weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open label, non-randomized, single-arm, extension safety study to
      evaluate the long-term safety of SPARC0913. Subjects who completed the prior evaluator-masked
      clinical non-inferiority Study participated in the current study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With AEs</measure>
    <time_frame>24 weeks</time_frame>
    <description>Subjects with treatment emergent adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change in IOP From Baseline to Visit 7 (End of Evaluations Visit)</measure>
    <time_frame>24 weeks</time_frame>
    <description>From the start of study (baseline visit) through week 24 (Visit 7, end of evaluations visit), the change in IOP was measured</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">161</enrollment>
  <condition>Open Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>SPARC0913</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPARC0913</intervention_name>
    <description>One drop of SPARC0913 in affected eye once daily for 24 weeks</description>
    <arm_group_label>SPARC0913</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged ≥18 years

          -  Willing to participate and giving written informed consent

          -  Willing to commit to study medication-dosing, study visits and follow-up visits to
             complete evaluation

          -  Eligible to receive Latanoprost once a daily as monotherapy for treatment of glaucoma

        Exclusion Criteria:

          -  History of allergic hypersensitivity or poor tolerance to latanoprost

          -  History of Substance abuse or addiction (alcohol drugs) in the past 3 years

          -  History of chronic use of concomitant medications in neurologic or psychiatric illness
             that would affect assessment of safety and effectiveness of the study medication

          -  Any abnormality preventing IOP measurement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SPARC study site</name>
      <address>
        <city>NC</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2009</study_first_submitted>
  <study_first_submitted_qc>July 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2009</study_first_posted>
  <results_first_submitted>December 28, 2015</results_first_submitted>
  <results_first_submitted_qc>April 1, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 5, 2016</results_first_posted>
  <last_update_submitted>May 23, 2016</last_update_submitted>
  <last_update_submitted_qc>May 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glaucoma</keyword>
  <keyword>Ocular hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was an extension study of previous study conducted by SPARC (CLR_09_12).
This was open-label, single group assignment long-term safety study.
A total of 161 subjects were enrolled in this study.
From the start of the study through Week 24 (Visit 7), safety endpoints (TEAEs and change introocular pressure) were evaluated</recruitment_details>
      <pre_assignment_details>Subjects received their first dose of the study drug at Visit 1 (Baseline Visit). A total of 149 subjects completed Study Visit 7 (End-of-Evaluations), which met FDA’s recommendation of providing safety data for at least 100 subjects for at least 6 months.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>SPARC0913</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="161"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="149"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A total of 161 subjects enrolled in the study. Subjects received their first dose of the study drug at Visit 1 (Baseline Visit). A total of 149 subjects completed Study Visit 7 (End-of-Evaluations), which met FDA’s recommendation of providing safety data for at least 100 subjects.</population>
      <group_list>
        <group group_id="B1">
          <title>SPARC0913</title>
          <description>Inhaled dose of SPARC0913. Each single dose was administered as 1, 2, 4 and 8 puffs from the inhaler.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="161"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.5" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With AEs</title>
        <description>Subjects with treatment emergent adverse events</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SPARC</title>
            <description>The number and percentage of subjects reporting a TEAE were tabulated by system organ classification and preferred terms.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With AEs</title>
          <description>Subjects with treatment emergent adverse events</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in IOP From Baseline to Visit 7 (End of Evaluations Visit)</title>
        <description>From the start of study (baseline visit) through week 24 (Visit 7, end of evaluations visit), the change in IOP was measured</description>
        <time_frame>24 weeks</time_frame>
        <population>From the start of the study through Week 24 (Visit 7, End of Evaluations), the change in IOP is evaluated</population>
        <group_list>
          <group group_id="O1">
            <title>SPARC0913</title>
            <description>SPARC0913: One drop of SPARC0913 in affected eye once daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in IOP From Baseline to Visit 7 (End of Evaluations Visit)</title>
          <description>From the start of study (baseline visit) through week 24 (Visit 7, end of evaluations visit), the change in IOP was measured</description>
          <population>From the start of the study through Week 24 (Visit 7, End of Evaluations), the change in IOP is evaluated</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.83" spread="4.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 weeks</time_frame>
      <desc>Of the 161 enrolled subjects in the study, 149 subjects received at least 24 weeks of SPARC's latanoprost treatment (completed the End-of-Evaluations i.e. Week 24), which met FDA’s recommendation of providing safety data for at least 100 subjects.</desc>
      <group_list>
        <group group_id="E1">
          <title>SPARC0913</title>
          <description>From the start of the study through Week 24 (Visit 7, End of Evaluations) adverse events were evaluated</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Epididymitis orchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute tension headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Carotid stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
              <event>
                <sub_title>Syncopal episode</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral vascular disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="140" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pain, ocular hyperemia, growh of eyelashes</sub_title>
                <description>eyelash thickening, eye discharge, conjunctival hyperemia, erythema of eyelid, punctate keratitis, visual acuity reduced, dry eye, cataract, conjunctival hemorrhage, eyelash discoloration, vitreous detachment, conjunctival edema</description>
                <counts group_id="E1" events="319" subjects_affected="140" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema peripheral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza, Sinusitis, Conjunctivitis viral, Tooth infection</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Any PT</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness,Visual field defect</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>any PT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Madarosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Shravanti Bhowmik</name_or_title>
      <organization>SPARC</organization>
      <email>shravanti.bhowmik@sparcmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

